What is it about?
Several computer-aided drug design (CADD) methods enable design and development of novel chemical entities. Structure-based drug design (SBDD) and the knowledge of in silico methods enable the visualization of the binding process of ligands to targets and to predict the key binding pocket sites and affinity of ligands to their target macromolecules.
Featured Image
Photo by Dan Gold on Unsplash
Why is it important?
To identify novel N-2-amino-N-phenyl quinoline-3-carboxamide (AQCMs) derivatives targeting Platelet derived growth factor receptor (PDGFR) to cure cancer using in silico approach.
Perspectives
In silico results reveals that all designed compounds had acceptable pharmacokinetic properties, found to be orally bio available and less harmful. Molecules from 36 to 39 showed better docking scores as compared to standard drugs sunitinib and tasquinimod.
Dr. Ganesh Shankar Mhaske
IVM’s Krishnarao Bhegade Institute of Pharmaceutical Education and Research, Talegaon Dabhade, Pune, Maharashtra, India
Read the Original
This page is a summary of: In Silico Identification of Novel Quinoline-3-carboxamide Derivatives
Targeting Platelet-Derived Growth Factor Receptor, Current Cancer Therapy Reviews, May 2022, Bentham Science Publishers,
DOI: 10.2174/1573394718666220421111546.
You can read the full text:
Resources
Contributors
The following have contributed to this page
